Dr. Berry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2500 NE Neff Rd
Bend, OR 97701Phone+1 541-706-5800
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Gynecologic Oncology, 2005 - 2008
University of Wisconsin Hospitals and ClinicsResidency, Obstetrics and Gynecology, 2001 - 2005
Oregon Health and Science University School of MedicineClass of 2001
Certifications & Licensure
OR State Medical License 2008 - 2025
IL State Medical License 2005 - 2017
WI State Medical License 2002 - 2005- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
- Electronic Patient Reported Symptom Assessment Start of enrollment: 2012 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsEfficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trialMathew Cowan, Wendy M. Swetzig, Valery Adorno-Cruz, Mario Javier Pineda, Nikki L. Neubauer
Gynecologic Oncology. 2021-10-01 - 19 citationsA phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, f...Roisin E. O'Cearbhaill, Wei Deng, Lee-may Chen, Joseph A. Lucci, Kian Behbakht
Gynecologic Oncology. 2019-12-01 - 396 citationsPatient-Customized Oligonucleotide Therapy for a Rare Genetic DiseaseJinkuk Kim, Chunguang Hu, Christelle Moufawad El Achkar, Lauren E. Black, Julie Douville
The New England Journal of Medicine. 2019-10-09
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
